Sunmnary Thyroid dysfunction is a well-recognised side-effect of treatment with interleukin-2 (IL2). We assessed the correlation between the development of abnormal thyroid function and tumour response in 13 patients receiving IL2 and interferon-2a (IFN2a) for advanced malignancy.
Seven patients had normal thyroid function during treatment, and all of these patients have since died of progressive disease. Of six patients who did develop thyroid dysfunction during treatment, one patient has died of progressive disease. However, statistically we were unable to confirm a definite correlation between the development of thyroid dysfunction and survival in this small group of patients.
Over the past 14 years Interleukin-2 (IL-2) has been extensively investigated as an anti-tumour agent. Its main role at present is in the treatment of metastatic renal cell carcinoma and malignant melanoma, where IL-2 has been used alone and also in combination with other agents such as interferon, lymphokine-activated killer (LAK) cells or tumour-infiltrating lymphocytes (TIL). Documented response rates in renal cell carcinoma and malignant melanoma in patients treated with IL-2, or with combinations of IL-2 and one of the above agents, range from 20-40% Rosenberg et al., 1989) . Treatment with IL-2 is associated with a well-documented range of side-effects (Lotze et al., 1986b; Parkinson, 1988; Lotze et al., 1986a Statistical analysis Differences in survival between groups were analysed using a log-rank test. Further statistical analysis of these data was complicated by the fact that patients failing to respond to treatment were withdrawn after two treatment cycles, while those patients responded to treatment continued on study. In order to determine whether abnormal thyroid function was a predictor of survival, while allowing for the longer treatment period in responding patients, we used a time-dependent Cox model to analyse these data.
Results
Seventeen patients have been treated according to this protocol. One patient had a history of previous thyroidectomy and was found to be hypothyroid prior to commencing treatment, and was excluded from further analysis. Three patients received two treatment cycles or fewer. All three were in progressive disease at the time of withdrawal from the study, and all have since died of progressive disease. Thyroid function tests on these three patients were normal while on treatment. However, as thyroid dysfunction did not develop in most patients until the third treatment cycle or later, these three patients were also excluded from further analysis. Thirteen patients were therefore evaluated for this study. The clinical characteristics are summarised in Table I Five patients had progressive disease with no response to treatment and were therefore withdrawn from the study after two months (four treatment cycles). All of these patients have since died of progressive disease.
One patient had stable disease and continued on treatment for a total for 5 months (13 treatment cycles). She then developed refractory hypotension associated with IL-2 infusion, and was withdrawn from further treatment. A second patient was assessed as having stable disease after four treatment cycles, but was withdrawn from the treatment protocol at her own request. Both these patients have since died of progressive disease.
Two patients with stable disease at 6 months (12 cycles) (Figure 2 ).
All those who maintained normal thyroid indices have died between 1.5 and 7 months after starting therapy. The median survival of this group is 3 months (range 1.5-7 months). Using a log-rank test, the difference in survival between these two groups is significant with P = 0.049. However, using a time dependent Cox model to determine whether the development of thyroid dysfunction was a positive predictor of survival, the difference between the groups was not significant (P = 0.7075), i.e. there was no significant correlation between survival and the development of thyroid dysfunction.
Discussion
The development of abnormal thyroid function has been well documented in association with treatment with alpha-interferon alone, IL-2 alone, IL-2 plus LAK cells, and IL-2 plus alpha-interferon (Atkins et al., 1988; Pichert et al., 1990 ).
The mechanism responsible for this phenomenon has not been fully elucidated, but it is probably an auto-immune phenomenon due to the induction of HLA class II antigens on thyroid epithelial tissue (Atkins et al., 1988; Pichert et al., 1990) . The aim of this study was to examine the possible correlation between the development of abnormal thyroid function and tumour response in a group of patients receiving IL-2 and IFN-2a for advanced malignancy.
In this prospective study of 17 patients serum T4 and TSH levels were measured every 2 weeks while on treatment. It is unlikely that transient abnormalities of thyroid function were missed in any patient. All patients had normal thyroid function prior to entry into the study.
Six of 13 patients developed some abnormality of thyroid function during treatment, and it was particularly striking that the pattern of thyroid abnormality which developed was similar in all these patients. This pattern has been previously noted (Pichert et al., 1990) in a study using the same protocol of therapy and correlates well with an auto-immune pattern. It is therefore of interest that none of these patients had anti-thyroid antibodies detected. The other seven patients had no abnormalities of thyroid function detected.
When survival is related to thyroid function, there is an obvious correlation between the development of abnormal thyroid function and longer survival. The median survival of those patients developing thyroid dysfunction was more than four times that of patients with normal thyroid status. However, the statistical analysis of this data is complicated by the longer time on treatment of responding patients. The point at issue is whether the development of abnormal thyroid function which occurred in these patients was due simply to treatment with IL2 and IFN-2a, or whether it truly predicts a tumour response to treatment. In five out of six patients abnormal thyroid function developed early in the course of treatment, between the second and fourth treatment cycles, and did not require long-term treatment with IL2 and IFN2a (Table II) (Hanafusa et al., 1983) . HLA class II expression can be induced on cultured thyroid cells by the addition of IFN-gamma, but not by adding IFN-alpha or IL-2 without IFN-gamma (Todd et al., 1985) . One action of IL-2 however is to induce IFNgamma production by T-lymphocytes, and possibly also by NK cells (Kasahara et al., 1983 
